AHA today encouraged the Centers for Medicare & Medicaid Services to work with Congress to require Medicare Advantage plans to waive prior authorization and other utilization management policies during public health emergencies, especially for hospitals transferring patients to post-acute care. 

While many plans worked with providers to waive or relax onerous prior authorization requirements during the COVID-19 emergency, others did not or only did so during the initial stages, exacerbating capacity issues, delaying patient care and resulting in inappropriate denials, AHA wrote, responding to a request for information on the issue included in CMS’ proposed rule for the MA program in 2023.

The AHA letter also points to issues and concerns regarding access to appropriate behavioral health specialties in MA, and recommends that CMS collect and publicly display data on the adequacy of MA behavioral health coverage. Finally, the letter offers general support for additional health plan oversight provisions included in the proposed rule.
 

Related News Articles

Headline
A report by the Department of Health and Human Services Office of the Inspector General found that many Medicare Advantage and Medicaid managed care plans…
Headline
The Senate Oct. 16 failed for a 10th time to advance the continuing resolution to extend government funding and end the ongoing shutdown. The chamber adjourned…
Headline
Medicare open enrollment for 2026 began Oct. 15 and runs through Dec. 7. During the annual enrollment period, Medicare-eligible individuals can check their…
Chairperson's File
Public
There is a saying that is very timely for our field: A smooth sea never made a skilled sailor. As we head into the final months of 2025, hospitals and health…
Headline
The federal government shutdown is expected to continue into next week as the Senate adjourned Oct. 9 after failing to pass spending legislation; senators plan…
Headline
The AHA provided a statement of record to the Senate Special Committee on Aging for a hearing Oct. 8 on the pharmaceutical and medical device supply chains.…